TOTAL VOLUME:
$95.1b
24H VOL:
$228,297,738
24H TRANSACTIONS:
906,796,923
OPEN INTEREST:
$2,086,068,444
797,194
Markets across
13,692
events
MATCHED EVENTS:
804
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
FDA approves Viatris' low-dose estrogen weekly patch? Odds & Prediction Markets
72%
chance
Time left: 17d:23h:12m
FDA approves Viatris' low-dose estrogen weekly patch?
$
$20
$50
$100
$500
Description
As of market creation, the FDA's expected decision date for the specified application is July 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds often diverge from published analyst forecasts because they reflect real-money incentives and continuous price discovery rather than point-in-time research reports. Traders in this market incorporate breaking news, regulatory signals, and clinical data faster than traditional research cycles, sometimes pricing in approval probabilities that differ meaningfully from Wall Street consensus. Comparing current odds to recent analyst commentary on the patch's regulatory pathway can reveal where the market sees upside or downside risk that consensus may have missed.
On Polymarket, traders set prices by buying and selling shares that represent yes or no outcomes for FDA approval. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The market price at any moment reflects the aggregate belief of all active traders, with higher prices indicating greater confidence in approval and lower prices suggesting skepticism. Liquidity and trading volume influence how quickly prices adjust to new information, so markets with deeper order books typically respond more efficiently to regulatory announcements or clinical updates.
This market resolves around Jul 30, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The resolution hinges on whether the FDA formally approves Viatris' low-dose estrogen weekly patch by that deadline. Traders should monitor FDA communications, regulatory calendars, and official company announcements to anticipate the timing and likelihood of a final decision.
Key catalysts include FDA advisory committee meetings, clinical trial data releases, and regulatory feedback letters from the agency. Competitive approvals in the hormone therapy space, manufacturing or safety updates from Viatris, and shifts in broader FDA policy on women's health products could also shift trader positioning. Media coverage of menopause treatment demand and reimbursement decisions by major insurers may influence market sentiment as well. Traders should track the FDA's official review timeline and any public statements from company executives or regulators.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.